Resistência genotípica aos Inibidores de Integrase
Capa do Boletim do Instituto Adolfo Lutz, volume 22, número 2, de 2012, com ilustração estilizada da fachada do prédio do instituto na parte inferior.
PDF (Português (Brasil))

Cómo citar

Minhoto LANÇA, A., de Macedo BRÍGIDO, L. F., de Souza CAVALCANTI, J., & de Paula FERREIRA, J. . L. (2012). Resistência genotípica aos Inibidores de Integrase. Boletim Do Instituto Adolfo Lutz - BIAL , 9–10. Recuperado a partir de https://periodicos.saude.sp.gov.br/BIAL/article/view/40059
PDF (Português (Brasil))

Citas

FDA. FDA approves new HIV drug: Raltegravir tablets used in combination with other antiretroviral agents. Administration USFaD, editor. FDA News; 2007

Markovitz M. Targeting Integrase: Mechanisms of Action and Mechanisms of Resistance to Integrase Inhibitors. Clinical Care Options; 2008.

Charpentier C, Karmockine M, Laureillard D, Tisserand P, Belec L, Weiss L, et al. Drug resistance profiles for the HIV Integrase gene in patients failing Raltegravir salvage therapy. HIV Med. 2008;9:765-70.

Hu Z, Kuritzkes DR. Effect of Raltegravir Resistance Mutations in HIV-1 Integrase on Viral Fitness. J Acquir Immune Defic Syndr. 2010;55:148-55.

Hackett JJ, Swanson P, Harris B, Holzmayer V, Yamaguchi J, Bodelle P, et al. Conf Retr. Opportunistic Infect. Comprehensive evaluation of HIV-1 integrase gene diversity in group m, n, and o viruses. Abstract. 2005;Feb:22-25:366.

Descargas

Los datos de descargas todavía no están disponibles.